.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Cipla
Boehringer Ingelheim
Dow
Fish and Richardson
Cerilliant
Harvard Business School
Deloitte
QuintilesIMS
US Army

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for Patent: RE39861

« Back to Dashboard

Which drugs does patent RE39861 protect, and when does it expire?


Patent RE39861 protects SEASONALE and is included in one NDA. There has been one Paragraph IV challenge on Seasonale.

This patent has ten patent family members in nine countries.

Summary for Patent: RE39861

Title:Methods of extended use oral contraception
Abstract:A method of female contraception involves administering a combination of estrogen and progestin for 60-110 consecutive days in which the daily amounts of estrogen and progestin are equivalent to about 5-35 mcg of ethinyl estradiol and about 0.025 to 10 mg of norethindrone acetate, respectively. The advantages include less menstrual bleeding, less patient anemia, less total exposure to medication, higher compliance rates and more lifestyle convenience for patients.
Inventor(s): Hodgen; Gary D. (Virginia Beach, VA)
Assignee: Duramed Pharmaceuticals, Inc. (Pomona, NY)
Application Number:10/893,795
Patent Claim Types:
see list of patent claims
Use; Device;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Teva Branded PharmSEASONALEethinyl estradiol; levonorgestrelTABLET;ORAL021544-001Sep 5, 2003ABRXYesYes► Subscribe► Subscribe► SubscribePREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: RE39861

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,898,032 Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: RE39861

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria216241► Subscribe
Canada2256977► Subscribe
Canada2596416► Subscribe
Germany69804918► Subscribe
Denmark0911029► Subscribe
European Patent Office0911029► Subscribe
Spain2175650► Subscribe
Japan2007197459► Subscribe
JapanH1129481► Subscribe
Norway982815► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Julphar
Queensland Health
Johnson and Johnson
Moodys
Mallinckrodt
QuintilesIMS
Colorcon
Teva
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot